scispace - formally typeset
J

Joseph E. Saavedra

Researcher at Leidos

Publications -  27
Citations -  1288

Joseph E. Saavedra is an academic researcher from Leidos. The author has contributed to research in topics: Prodrug & Nitric oxide. The author has an hindex of 15, co-authored 27 publications receiving 1213 citations. Previous affiliations of Joseph E. Saavedra include George Mason University & University of Michigan.

Papers
More filters
Journal ArticleDOI

Nitric Oxide-Releasing Polymers Containing the (N(O)NO) - Group

TL;DR: The results suggest that polymers containing the [N(O)NO]- functional group may hold considerable promise for a variety of biomedical applications in which local delivery of NO is desired.
Journal ArticleDOI

Localizing Antithrombotic and Vasodilatory Activity with a Novel, Ultrafast Nitric Oxide Donor

TL;DR: In this paper, the reaction of nitric oxide (NO) with l-proline in methanolic sodium methoxide yields a diazenium-diolate product, C5H7N3O4Na2·CH3OH (PROLI/NO), that can be stabilized in basic solution but that dissociates to proline (1 mol) and NO (2 mol) with a half-life of only 1.8 s at pH 7.4 and 37 °C.
Journal ArticleDOI

The Fenton oxidation mechanism: reactivities of biologically relevant substrates with two oxidizing intermediates differ from those predicted for the hydroxyl radical.

TL;DR: Competition studies demonstrate reactivity patterns for X and Y that are clearly distinct from the pattern predicted for the hydroxyl radical, the intermediate commonly invoked in discussions of Fenton oxidations.
Journal ArticleDOI

Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and double JS-K, through incorporation into PEG-protected nanoparticles

TL;DR: The nanoparticle stabilized PABA/NO are protected from attack by glutathione as evidenced by a significant increase in time taken for 50% decomposition, and this combination of PEG-protected nanoparticles with sizes appropriate for cancer targeting by enhanced permeation and retention (EPR) and delayed release of NO may afford enhanced therapeutic benefit.